Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$19.98 USD
-0.28 (-1.38%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $19.97 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
Brokerage Reports
0 items in cart
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 601 - 620 ( 722 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
INITIATING COVERAGE AT BUY AND TARGET PRICE $109
Provider: NATIONAL ALLIANCE CAPITAL MARKETS
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Positive Nerve Block Results Could Lead to sNDA Approval in Q2:15; Reiterate OUTPERFORM and Raising PT to $92
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q4 Financials: EXPAREL Utilization Continues to Broaden and New Customer Adds Accelerate; Reiterate OUTPERFORM and PT Goes to $81
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 24
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q4:13 Preview: Not Expecting Any Surprises Given EXPAREL Revenues Already Preannounced; Jan. Symphony Health Data for EXPAREL; Reiterate OP and $78 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q4:13 Preview: Not Expecting - Any Surprises Given EXPAREL Revenues Already Preannounced; Jan. Symphony - Health Data for EXPAREL; Reiterate OP and $78 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Posidur Receives Complete Response Letter from FDA, Leaving EXPAREL as the Only Long-Acting Bupivacaine on the Market; Reiterate OUTPERFORM and $78 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Posidur Receives Complete Response Letter from FDA, Leaving EXPAREL as the Only Long-Acting Bupivacaine on the Market
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
February and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
February and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Additional Phase 4 Results Build Upon Clinical Evidence Supporting EXPAREL Use in iTAP Procedures; Reiterate OUTPERFORM and $78 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Additional Phase 4 Results Build Upon Clinical Evidence Supporting EXPAREL Use in iTAP Procedures
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
December Symphony Health Data and Corporate Update; Reiterate OUTPERFORM and $78 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Preannounced Q4 EXPAREL Sales Soundly Beat Expectations; Reiterate OUTPERFORM; Raising PT to $78
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Results From Third IMPROVE Trial Demonstrate Benefits of EXPAREL in Minimally Invasive Surgery; Reiterate OUTPERFORM and $59 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R